Viking Therapeutics (NASDAQ:VKTX) stock is soaring on Thursday, extending the momentum it picked up in Wednesday’s after‑hours session following the company’s fourth‑quarter earnings release.
- Viking Therapeutics shares are showing limited movement. Where is VKTX stock headed?
What The Numbers Showed
Viking posted a loss of $1.38 per share, worse than the 89 cent loss analysts were expecting. Last quarter, the company only missed on EPS by 13 cents, according to Benzinga Pro.
The miss was driven by a sharp increase in research and development spending, which jumped to $153.5 million, up from $31 million a year earlier.
CEO Brian Lian put the quarter into perspective, noting that “the past year was an exceptional year for Viking, marked by rapid progress across our obesity portfolio.”
VK2735 Advances On Both Injectable And Oral Fronts
The company’s Phase 3 VANQUISH program for its subcutaneous VK2735 obesity drug is moving quickly, with the goal of being used …